Introduction {#S0001}
============

Primary non-Hodgkin's lymphoma of the testis (PTL) is an uncommon disease, accounting for approximately 9% of all testicular neoplasms and 1%--2% of all non-Hodgkin's lymphomas.[@CIT0001],[@CIT0002] PTL is the most common testicular malignancy in men older than 50 years, presenting as focal masses with epididymal and scrotal involvement.[@CIT0003] Diffuse large B-cell lymphoma (DLBCL) is the most common histotype in primary forms, accounting for 80%--90% of cases.[@CIT0004] PT-DLBCLs that arise in sites previously considered to be immune sanctuaries show inferior responses to therapies. In the largest series of PTL patients reported to date, the outcome was very poor with a 5- and 10-year overall survival (OS) of 48% and 27%, respectively[@CIT0005],[@CIT0006] The distinctive clinical and pathological characteristics of PT-DLBCL suggest that this entity might have a unique molecular and biological signature.[@CIT0007] However, the pathogenesis of PT-DLBCL is poorly understood.

Nuclear factor-kappa B (NF-κB) is a transcription factor that regulates different cellular processes such as cell proliferation and survival and is normally transiently activated by antigen-dependent stimulation in B cells.[@CIT0008] Aberrant activation of NF-κB is largely known to promote oncogenic characteristics such as anti-apoptosis, proliferation, and changes in cell adhesion.[@CIT0009],[@CIT0010] Oncogenic NF-κB activities have been demonstrated in various hematologic malignancies, including lymphoplasmacytic lymphoma, DLBCL, mucosa-associated lymphoid tissue lymphoma, multiple myeloma, Hodgkin lymphoma, and some leukemias.[@CIT0011]--[@CIT0015]

In DLBCL, the mechanism of constitutive activation of the NF-κB pathway has been traced to somatic genetic alterations in the upstream pathway components.[@CIT0016] A recent gene expression profile-based molecular classification of DLBCL distinguished two main subtypes: activated B-cell-like (ABC) lymphoma and germinal center B cell (GCB)-like lymphoma.[@CIT0017] ABC-DLBCLs exhibit increased baseline NF-κB activity and more frequent genetic alterations of the chronic active B-cell receptor (BCR) signaling pathway components, including mutations of *CARD11* and/or *CD79B*, and the Toll-like receptor (TLR) signaling pathway component myeloid differentiation primary response gene 88 (*MYD88*).[@CIT0015],[@CIT0018]--[@CIT0020] These alterations are only detected in a subset of ABC-type DLBCL cases (*MYD88*, 29%; *CD79B*, 18%; and *CARD11*, 10%).[@CIT0015] However, recent studies indicate that the prevalence of oncogenic *MYD88* mutations varies greatly among ABC-DLBCLs presenting at different anatomical sites.[@CIT0015],[@CIT0021],[@CIT0022] Interestingly, *MYD88* mutations were by far the most prevalent mutations detected in cases of immune-privileged site-associated DLBCL presenting in the central nervous system (75%) and testis (71%).[@CIT0023]

With the advent of various targeted therapeutic agents acting on NF-κB-related pathways,[@CIT0024]--[@CIT0026] knowledge of the frequency of individual NF-κB-affecting mutations and the clinicopathological impact of such mutations would be valuable. In particular, identification of molecules involved in BCR and MYD88 signaling can provide a genetic tool to identify patients that may benefit from personalized treatment targeting these pathways. However, previous studies on the *CD79B* and *MYD88* mutations in PT-DLBCL are limited[@CIT0023],[@CIT0027],[@CIT0028] and the clinical significance of *MYD88* mutations remains unclear. Furthermore, the mutational status of *CD79B* and *MYD88* in Chinese PT-DLBCL patients has not been elucidated. In this study, we examined the prevalence, clinicopathologic characteristics, and prognosis of *CD79B* and *MYD88* mutations in a cohort of Chinese patients with PT-DLBCL.

Materials And Methods {#S0002}
=====================

Patient Samples {#S0002-S2001}
---------------

This retrospective study was performed on 30 patients with PT-DLBCL originally diagnosed and treated at Fujian Cancer Hospital and Zhejiang Cancer Hospital, China between January 2003 and June 2016. According to the literature,[@CIT0029] primary testicular lymphoma was defined as a lymphoma that presented with a clinically dominant and primary testicular mass, and also allowed the inclusion of patients who were ultimately shown to have advanced-stage disease. When the testis became involved after systemic lymphoma was diagnosed, the lymphoma was regarded as a secondary testicular lymphoma. Cases of secondary testicular DLBCL were excluded from the selection. Three expert pathologists reviewed all cases according to the 2017 World Health Organization classification of tumors of hematopoietic and lymphoid tissues.[@CIT0030] All patients underwent orchidectomy with or without chemotherapy. The first-line chemotherapy regimen was mostly cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP), or rituximab plus CHOP (R-CHOP). Ten samples of normal lymph nodes derived from patients visiting Fujian Cancer Hospital were collected and considered as a control group. This study was carried out in accordance with the Declaration of Helsinki and written informed consent was obtained from the patients or their legal guardians. The study protocol was approved by the institutional review boards of Fujian Cancer Hospital and Zhejiang Cancer Hospital.

Immunohistochemistry Analysis {#S0002-S2002}
-----------------------------

Immunohistochemical analysis was performed using fully automated protocols on a Bond-III Autostainer (Leica Biosystems, Melbourne, Australia). Four-micrometer-thick sections of formalin-fixed paraffin-embedded (FFPE) tissue were subjected to staining protocols with the following antibodies: CD20, CD3, CD10, BCL-6, MUM-1, Ki-67, BCL-2, MYC, p65, and MYD88. Detailed information regarding the primary antibodies and their sources, dilution ratios, clones, and cut-off values are shown in [Table 1](#T0001){ref-type="table"}. Germinal center B cell (GCB) subtype of DLBCL and non-GCB subtype of DLBCL were classified based on immunohistochemical staining of CD10, BCL-6, and MUM-1 by Hans' algorithm.[@CIT0031] We used a scoring system for MYD88 expression according to previous reports.[@CIT0027],[@CIT0032] The staining intensity of the cytoplasm was scored as either 0 (negative), 1 (weak), 2 (moderate), or 3 (intense), and the extent of staining was scored as either 0 (0% of the tumor area stained), 1 (\<10%), 2 (10%--50%), or 3 (\>50%). These two parameters were combined to reach a final score ranging from 0 to 6. Final scores of 5 or 6 were classified as high MYD88 expression and scores of 0--4 were classified as low expression.Table 1Detailed Information Of Primary Antibodies And Their Cut-Off ValuesAntibodySourceCloneDilutionCut-Off ValueCD20MXB BiotechnologiesL26Ready-to-useCD3MXB BiotechnologiesSP7Ready-to-useCD10Dako56C6Ready-to-use30%BCL-6DakoPG-B6pReady-to-use30%MUM-1DakoMUM1pReady-to-use30%Ki-67DakoMIB-1Ready-to-useBCL-2Dako124Ready-to-use70%MYCAbcamY691:50040%p65Santa Cruzsc-1091:30030%MYD88AbcamEPR590(N)1:100

CD79B And MYD88 Mutation Analysis {#S0002-S2003}
---------------------------------

Genomic DNA was isolated from three pieces of a 5-μm-thick section of the FFPE tumor tissue using the QIAamp FFPE DNA Tissue Kit (Qiagen, Germantown, MD, USA) according to the manufacturer's instructions. PCR was carried out using AmpliTaq Gold polymerase (Applied Biosystems, Weiterstadt, Germany) according to the manufacturer's instructions under the following conditions: 94°C for 5 min followed by 34 cycles of denaturation for 30 s at 94°C, annealing for 30 s at 60°C, and extension for 45 s at 72°C. The primer pairs for *CD79B* (exon 5) and *MYD88* (exon 5) were designed using Primer-BLAST as follows: *CD79B*-5F (5′-GGGCTGGGGGACACTAACACTC-3′), *CD79B*-5R (5′-TGGGTGCTCACCTACAGACCAC-3′), *MYD88*-5F (5ʹ-AACCCTGGGGTTGAAGACTG-3ʹ), and *MYD88*-5R (5ʹ-AGTCTTCAGGGCAGGGACAA-3ʹ). The PCR products were routinely purified and sequenced in both directions using the BigDye Terminator version 3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). At least two independent PCR and sequencing experiments were conducted to confirm mutations, which were proven not to be single nucleotide polymorphisms via reference to the National Center for Biotechnology Information dbSNP database.

MYD88 Copy Number Analysis {#S0002-S2004}
--------------------------

Quantitative real-time PCR was performed to analyze the copy number status of *MYD88* with normalization using the reference gene *RPP30*, a single copy gene encoding the ribonuclease P/MRP 30-kDa subunit.[@CIT0027] The primer pairs used for *MYD88* and *RPP30* were as follows: *MYD8*8F 5′-GATCCCCATCAAGTACAAGGCAA-3′, *MYD88*R 5′-AAGGCGAGTCCAGAACCAAG-3′, *RPP30*F 5′-GCCCGGCTCTATGATGTTGT-3′, and *RPP30*R 5′-TCCAGATGAGTCAAAACAGGTCA-3′. The quantitative PCR was carried out using Stratagene Mx3000P (Agilent, Germany) according to the manufacturer instructions. In brief, 20 ng of genomic DNA from the FFPE tissue and 300 nM of primer in a final volume of 20 μL with SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) was amplified under the following thermal cycling conditions: enzyme activation for 3 min at 98°C followed by 45 cycles of denaturation for 15 s at 98°C, and annealing, extension, and plate reading for 30 s at 60°C. Because the estimated PCR efficacies of *MYD88* and *RPP30* were almost identical and very close to 100% (94.6% and 95.1%, respectively), we quantified the *MYD88* copy number (*MYD88*/*RPP30*) using the ΔCT method.[@CIT0027]

Statistical Analysis {#S0002-S2005}
--------------------

SPSS software (version 19.0, IBM, Armonk, NY, USA) was used for all statistical analyses. The patient characteristics were compared across different subgroups using Fisher's exact test. Correlation analysis of the categorical variables was analyzed using the chi-squared test. OS was determined from the date of diagnosis to the date of death caused by lymphoma or termination of follow-up. Univariate analysis and survival curves were generated by the Kaplan-Meier method and compared using the log rank test. Multivariate analysis was conducted with the Cox proportional hazards model. A *P*-value of \<0.05 was considered statistically significant.

Cell Culture, Retroviral Constructs, And Transduction, And Western Blotting {#S0002-S2006}
---------------------------------------------------------------------------

TMD8 and LY1 cell lines were cultured in RPMI 1640 medium containing 10% FBS (Gibco, Carlsbad, CA, USA) and 100 U/mL of penicillin and streptomycin (Invitrogen, Carlsbad, CA, USA). Cells were maintained at 37°C in 5% CO~2~ in a humid atmosphere.

Point mutations were made to generate *MYD88*^L265P^. *MYD88* mutants were created with the Phusion site-directed mutagenesis kit according to the manufacturer's instructions (New England BioLabs), using vLyt2-MYD88-EGFP vector as templates. All cDNA inserts from PCR cloning and site-directed mutagenesis were verified by sequencing. The *MYD88* mutagenesis primers were as follows: L265P forward P-CATCAGAAGCGACCGATCCCCATCAAG and L265P reverse P GGCACCTGGAGAGAGGCTGAGTGCAAA. For transfer into a retroviral vector system, *MYD88*^WT^ and *MYD88*^L265P^ were amplified by polymerase chain reaction using Phusion polymerase (New England Biolabs) according to the manufacturer's recommendations.

HEK293T cells (150,000 cells per well of a 6-well plate) were transfected using Lipofectamine 2000 (Invitrogen) with 1 μg to 5 μg of plasmids. Stable cell lines were made by transfection of HEK293T cells with the respective plasmids and then selection with blasticidin (Sigma-Aldrich) for 1 week. Pools of stable lines expressing GFP alone or GFP-tagged proteins were used for the experiments.

Whole cell lysates were subjected to 4%--12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride (PVDF) membranes (Invitrogen), followed by incubation with primary antibodies. The following antibodies were used: anti-phospho p65 and anti-phospho STAT3 (Tyr705) (Cell Signaling Technology, Denvers, MA, USA).

Results {#S0003}
=======

Clinical Characteristics {#S0003-S2001}
------------------------

The study group included 30 patients with PT-DLBCL. The patients' ages at diagnosis ranged from 38 to 85 years with a median age of 62 years. Seventeen patients (56.7%) were older than 60 years. The main symptoms of the PT-DLBCL (painless testicular mass) were initially present on the left side in 12 patients (40%), right side in 15 patients (50%), and bilaterally in three patients (10%). Complete clinical information was recorded for all patients. B symptoms were identified in four (13.3%) patients. There were five (16.7%), 13 (43.3%), five (16.7%), and seven (23.3%) patients with Ann Arbor stages I, II, III, and IV disease, respectively. Furthermore, there were 21 (70.0%) and nine (30.0%) patients with low International Prognostic Index (IPI) and high IPI, respectively. Clinical outcomes were available for 26 patients included in the study. At the time of the last clinical follow-up (range, 4--56 months), six (23.1%) patients had died, and the median OS was 24 months. The 3-year OS rate was 73.20%.

Morphological And Immunophenotypic Features {#S0003-S2002}
-------------------------------------------

A representative image of the histomorphology of PT-DLBCL is shown in [Figure 1](#F0001){ref-type="fig"}. All orchidectomy specimens showed diffuse proliferation of large neoplastic lymphocytes. A seminiferous tubule entrapped by lymphoma cell infiltration was also present. Atypical large lymphocytes had large irregular nuclei with one or more prominent nucleoli. A high mitotic rate and atypical mitoses were common findings in most cases.Figure 1Representative hematoxylin and eosin (H&E) staining of PT-DLBCL and immunostaining of MYD88. (**A**) Orchidectomy specimens showing diffuse proliferation of large neoplastic lymphocytes (H&E, ×200). (**B**) Atypical large lymphocytes had large irregular nuclei with one or more prominent nucleoli (H&E, ×400). MYD88 is expressed in the cytoplasm of lymphoma cells. Intensity scoring of MYD88 immunohistochemistry: (**C**) 0, negative; (**D**) 1, weak; (**E**) 2, moderate; and (**F**) 3, intense (×400).

All cases were strongly positive for CD20 and negative for CD3. According to Hans's algorithm, 26/30 (86.7%) cases demonstrated a non-GCB immunophenotype, whereas 4/30 (13.3%) cases demonstrated a GCB immunophenotype. The ratio of GCB to non-GCB phenotype was 1:6.5. The Ki-67 proliferation rate was generally high, with a median of 60% and a range of 50%--90%. There were 25/30 (83.3%) and 13/30 (43.3%) cases that tested positive for BCL-2 and MYC, respectively, and 11/30 (36.7%) cases were positive for both BCL2 and MYC (double expression). Twenty-three (76.7%) cases expressed the NF-κB subunit p65. The MYD88 protein was expressed in 26/30 (86.67%) cases with high degrees of intensity ([Figure 1](#F0001){ref-type="fig"}). The expression pattern of MYD88 exhibited no correlation with the patient's age (*P*=1.000), location (*P*=0.406), Ann Arbor stage (*P*=0.913), and non-GCB/GCB subtype (*P*=0.65) ([Table 2](#T0002){ref-type="table"}). However, the MYD88 protein stain was significantly associated (*P*=0.037) with *MYD88* missense mutation ([Table 3](#T0003){ref-type="table"}).Table 2Clinicopathologic Characteristics Of PT-DLBCL With CD79B And MYD88 Mutations And MYD88 ExpressionParameterNo. Patients*CD79B* Y196*pMYD88* L265P*p*MYD88*p*Location0.6380.8800.406 Left135810 Right1781016Age (years)0.5990.0941.000 ≤60124510 \>601891316Ann Arbor stage0.6380.5470.913 I-II1881115 III-IV125711IPI score0.6840.7920.582 Low (0--2)\
 High (3--5)21\
99\
413\
519\
7Cell-of-origin0.4061.0000.913 GCB4333 Non-GCB26101523BCL-20.0991.0000.317 Positive26131622 Negative4024BCL-2/c-MYC0.8381.0000.970 Positive11479 Negative1991117P650.2860.7920.582 Positive23121319 Negative7157 Table 3Correlation Between *MYD88* Mutational Status, Amplification, And Its Protein ExpressionMYD88No. Patients*MYD88* L265P*pMYD88* Amplification*p*MutantWild TypePresentAbsentPositive261880.03714120.141Negative40404

Mutational Status Of CD79B And MYD88 And Clinicopathological Associations {#S0003-S2003}
-------------------------------------------------------------------------

With respect to the mutation status, *CD79B* exon 5 and *MYD88* exon 5 were successfully amplified in all samples. At least one mutation of the two genes analyzed was detected in 22/30 (73.3%) cases, with 18/30 (60.0%) cases showing *MYD88* mutation and 13/30 (43.3%) cases showing *CD79B* mutation. All 13 patients who harbored *CD79B* mutations showed missense mutations. The main affected position (Y196) was the first tyrosine of the immunoreceptor tyrosine-based activation motif (ITAM) domain ([Figure 2](#F0002){ref-type="fig"}). The overall frequency of mutation was higher in our cohort than reported previously. All 18 *MYD88* mutations were L265P, an evolutionarily invariant residue in the hydrophobic core of the Toll/interleukin (IL)-1 (TIR) receptor domain of MYD88 ([Figure 2](#F0002){ref-type="fig"}). The *MYD88*^L265P^ mutation coexisted with a *CD79B* mutation in eight cases, which constituted 61.5% of *CD79B* mutations identified and 44.4% of *MYD88*^L265P^ cases. Intriguingly, *CD79B* and *MYD88* mutations were more prevalent in the non-GCB subtype (83.3% and 76.9%, respectively) and were relatively uncommon in the GCB subtype (16.7% and 23.1%, respectively). The *MYD88* and *CD79B* mutational status showed no significant correlation with the patient's age, location, Ann Arbor stage, IPI, and non-GCB/GCB subtype ([Table 2](#T0002){ref-type="table"}).Figure 2Representative results of Sanger sequencing. (**A**) *MYD88*^L265P^. A CTG (leucine) codon was changed to a CCG (proline) codon. (**B**) *CD79B*.^Y196N^ A TAC (tyrosine) codon was changed to a CAC (histidine) codon. (**C**) *CD79B*.^Y196N^ A TAC (tyrosine) codon was changed to an AAC (asparagine) codon. (**D**) *CD79B*^Y196S^. A TAC (tyrosine) codon was changed to a TCC (serine) codon.

Amplification Status Of MYD88 {#S0003-S2004}
-----------------------------

In quantitative real-time PCR analysis, *MYD88* was successfully amplified in all cases. The copy number of *MYD88* in the PT-DLBCL cases ranged from 1.11 to 22.76 with a median of 4.19. Compared with the level detected in normal lymph nodes (range, 0.86--1.24; median, 1.005), the *MYD88* gene showed significant enhancement of amplification in PT-DLBCL cases (*P*\<0.01). However, there was no significant difference in the amplification status between PT-DLBCL cases harboring the *MYD88* wild type (median, 4.5; range, 1.52--22.76) and L265P mutation (median, 4.355; range, 1.11--20.15) (*P*=0.654). The amplification status (median, 4.67; range, 1.11--20.15) was not associated with the expression of *MYD88* (median, 2.435; range, 1.62--22.76) (*P*=0.141) ([Table 3](#T0003){ref-type="table"}).

Survival And Analysis Of Prognostic Factors {#S0003-S2005}
-------------------------------------------

Univariate analyses of the clinical, pathological, and genetic factors influencing the OS of patients with PT-DLBCL are summarized in [Table 4](#T0004){ref-type="table"}. Univariate analysis showed that high IPI and advanced stage (stage III--IV) were associated with worse outcome (*P*\<0.001 and *P*=0.036, respectively; [Figure 3](#F0003){ref-type="fig"}). *MYD88*^L265P^ and BCL-2/c-MYC co-expression were marginally associated with a shorter OS (*P*=0.053 and *P*=0.055, respectively). However, the *CD79B* mutational status and expression level of MYD88 did not affect the prognosis (*P*=0.947 and *P*=0.719, respectively). The factors most predictive of OS by univariate analysis were then included in the multivariate analysis. Because of the small sample size, no independent prognostic factor was associated with OS, although advanced stage (*P*=0.071, hazard ratio 3.264, 95% confidence interval 0.015--1.185) showed a trend toward worse OS.Table 4Univariate Analysis In 26 Patients With PT-DLBCLParameterOS95% CIp valueLocation0.591 Left46.8032.51--61.09 Right46.8033.28--60.32Age (years old)0.131 \<6050.3040.49--60.01 ≥6046.8033.97--59.63Ann Arbor stage0.036 I-II52.9048.03--57.84 III-IV33.0020.18--45.82IPI score\<0.001 Low (0--2)51.0044.713--57.287 High(3--5)20.0015.706--24.294Cell-of-origin0.460 GCB51.00- Non-GCB46.8026.86--66.74BCL-20.799 Positive46.8035.33--66.68 Negative51.00-BCL-2/c-MYC0.055 Positive51.0024.25--77.75 Negative46.8019.92--73.68P650.206 Positive52.0040.63--61.37 Negative18.00-CD79B Y1960.947 Mutant45.0934.78--55.39 Wild type45.3338.19--52.48*MYD88* L265P0.053 Mutant51.00- Wild type46.8029.17--64.44MYD880.719 Positive51.00- Negative43.6737.72--49.62 Figure 3Univariate survival analysis of patients with PT-DLBCL. Overall survival (OS) of 26 patients with PT-DLBCL. (**A**). High IPI and advanced stage (stage III--IV) was associated with worse outcome (*P*\<0.05). (**B** and **C**). However, the *MYD88* (**D**) and *CD79B* (**E**) mutational status and expression level of MYD88 (**F**) did not affect the prognosis (*P*\>0.05).

MYD88 Mutant Activate NF-κB And JAK--STAT3 Signaling {#S0003-S2006}
----------------------------------------------------

Western blot analysis of phosphorylated STAT3 (p-STAT3) and phosphorylated p65 (p-p65) protein expression in TMD8 and LY1 cell lines harboring retroviral constructs for WT *MYD88* or *MYD88* mutant are shown in [Figure 4](#F0004){ref-type="fig"}. Compared with the negative and blank controls, the expression of p-STAT3 and p-p65 proteins were significantly upregulated in the MYD88 mutant group, indicating that *MYD88* mutant activated NF-kB and JAK--STAT3 signaling.Figure 4Western blot analysis of p-STAT3 and p-p65 protein expression in TMD8 and LY1 cell lines harboring retroviral constructs for WT *MYD88* or *MYD88* mutant. The expression of p-STAT3 and p-p65 proteins were significantly upregulated in the *MYD88* mutant group.

Discussion {#S0004}
==========

DLBCL is the most common lymphoma subtype and accounts for 30%--40% of all cases of adult non-Hodgkin lymphoma.[@CIT0030],[@CIT0033] DLBCL represents a class of clinically, immunophenotypically, and genetically homogeneous lymphomas, which have been subdivided into morphological variants, molecular and immunophenotypical subgroups, and distinct disease entities such as primary central nervous system lymphoma and primary mediastinal large B-cell lymphoma. According to the 2017 version of the World Health Organization classification of lymphoid malignancies, PT-DLBCL is classified within the category of DLBCL, not otherwise specified.[@CIT0030] However, recent studies confirmed the unique features of PT-DLBCL, including its prevalence in older males, high risk of relapse, propensity to involve the central nervous system, and poor outcome. The distinctive clinical and pathological characteristics of PT-DLBCL suggest that it represents a unique subtype of DLBCL. In the present study, clinicopathological factors, including patient age, predominance of non-GCB subtype, and poor outcome, were in accordance with earlier studies.

Activation of the NF-κB pathway is a hallmark of ABC-DLBCL. NF-κB activation might be triggered by stimulation of either BCR, tumor necrosis factor, or the TLR pathway.[@CIT0016] Somatic mutations affecting the ITAM signaling modules of CD79B, and in some cases of CD79A, were detected frequently in ABC-DLBCL cell lines and biopsy samples but rarely in other DLBCLs and never in Burkitt's lymphoma or mucosa-associated lymphoid tissue lymphoma. *CD79B* mutations were shown to increase surface BCR expression and nullify the negative regulation of BCR, which were suggested to support the "chronic active" BCR signaling that leads to constitutive NF-κB activation in ABC-DLBCL. It was initially reported that *CD79B* mutations were present in 21% of ABC-DLBCL cases and 3% of GCB-DLBCL cases, although subsequent studies described a lower prevalence of only 8.5%--12.2%.[@CIT0014],[@CIT0023] In the current study, we found that the *CD79B* ITAM was mutated in cases of PT-DLBCL with a much higher prevalence of 43.3%. In accordance with a previous study,[@CIT0028] these mutations were predominantly present in cases of non-GCB-type DLBCL, occurring in 83.3% of non-GCB-DLBCLs but only in 16.7% of GBC-DLBCLs.

MYD88 is an adaptor protein of TLR and IL-1 receptors, which mediates the TLR and IL-1R signaling pathways in the innate immune response. MYD88 activates the NF-κB pathway through association with IL-1 receptor-associated kinase (IRAK)1 and IRAK4.[@CIT0007] Activating mutations in *MYD88* were initially identified in DLBCL by Ngo et al.,[@CIT0008] who showed that the most frequent and most oncogenic form was the L265P mutation of the TIR domain, which was detected in 29% of ABC-DLBCL cases but was relatively rare in GCB-DLBCL. *MYD88*^L265P^ forms a stable protein complex with IRAK1 and IRAK4 and promotes the constitutive activation of the NF-κB and JAK-STAT3 pathways, promoting malignant cell survival in these lymphomas. Our study demonstrated that the expression of p-STAT3 and p-p65 protein were upregulated in the mutant group, indicating that MYD88 mutant activated NF-κB and JAK--STAT3 signaling.

To date, *MYD88* mutations have been described in only 9% of gastric mucosa-associated lymphoid tissue lymphoma, 3% of chronic lymphocytic leukemia, 5% of Burkitt's lymphoma, and 29% of systemic ABC-DLBCL cases.[@CIT0007],[@CIT0008] Recent studies indicate that the prevalence of an oncogenic *MYD88* mutation varies greatly among ABC-DLBCLs presenting at different anatomical sites.[@CIT0015],[@CIT0021],[@CIT0022] Intriguingly, Kraan et al.[@CIT0023] found that *MYD88* mutations were by far the most prevalent mutation detected in cases of immune privileged-DLBCL presenting in the central nervous system (75%) or testis (71%), and were relatively uncommon in nodal (17%) and gastrointestinal tract lymphomas (11%). We observed *MYD88*^L265P^ mutations in 60.0% of the patients with PT-DLBCL. The frequency of mutations was lower than those reported by Kraan et al.[@CIT0023] and Oishi et al.[@CIT0027] (71% and 82%, respectively); however, interestingly, the percentage of coexistence of this mutation with *CD79B* mutations was much higher than those reported in previous studies.[@CIT0023],[@CIT0027],[@CIT0028]

Our study confirms the previous finding that *MYD88* and *CD79B* mutations are predominant in ABC-DLBCL and often coexist within the same tumor. Moreover, *MYD88* and *CD79B* mutations are strongly over-represented in lymphomas presenting outside of so-called "professional" lymphoid tissues, particularly in immune privileged-DLBCL. Mutational activation of TLR/MYD88 signaling endows lymphoma-initiating cells with a selective growth advantage at immune-privileged sites. The concomitant presence of *CD79B* mutations, causing chronically active BCR signaling, may further promote the selective outgrowth of the tumor cells within these relatively stimulus-poor microenvironments. Taken together, these immunological sanctuaries could contain unique microenvironments that facilitate the migration, implantation, and/or growth of *MYD88*- and/or *CD79B*-mutated lymphoma cells, which would contribute to the homogeneity of testicular and central nervous system DLBCLs.[@CIT0034]

In addition to the mutational status of *MYD88*, we also evaluated its copy number and protein expression. A previous study indicated that amplification of the *MYD88* locus is significantly more frequent in DLBCL cases with the *MYD88*^L265P^ mutant than in those with *MYD88* wild-type by array-based comparative genomic hybridization.[@CIT0015] However, our study showed that there was no significant difference in the amplification status between PT-DLBCL cases harboring the *MYD88* wild type and L265P mutation. Thus, different methods may lead to different experimental results. We found that *MYD88* was overexpressed in 86.67% of PT-DLBCL cases, which was higher than the rates reported by Choi et al.[@CIT0032] and Oishi et al.[@CIT0027] (38.7% and 65%, respectively). However, the amplification status was not associated with either the *MYD88* mutation frequency or its protein expression, which is in agreement with these studies.[@CIT0027],[@CIT0032] We also found that the expressional status of *MYD88* was independent of its L265P mutation frequency and was significantly associated with tumor recurrence and a shortened disease-free survival in patients with DLBCL. However, in the present study, neither *MYD88* mutations nor its expressional status affected the prognosis of PT-DLBCL, consistent with the data of Oishi et al.[@CIT0027]

Conclusion {#S0005}
==========

Our results suggest that *MYD88* and *CD79B* mutations are important drivers of lymphomagenesis in PT-DLBCL. Thus, patients with PT-DLBCL may also benefit from therapy targeting MYD88 and/or BCR signaling for personalized treatment. This unique molecular and biological signature suggests that PT-DLBCL represents a unique subtype of DLBCL.
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